How PD-L1 affects the stability of cancer-related mRNA
Official title: Regulation of mRNA homeostasis by PD-L1
Funded at St. John's University · NIH-11053611 · Data updated 2026-11-12
This study is looking at how a protein called PD-L1 affects the way certain genes help cancer cells survive in ovarian and prostate cancer, with the hope that understanding this could lead to better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. John's University NIH-funded |
| Lab location | 1 site (Queens, United States) |
| Project start | May 15, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $164,000 |
| NIH project number | 5R16GM149263-03 |
| Project ID | NIH-11053611 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with ovarian or prostate cancer who may benefit from advanced immunotherapy approaches.
✕Less likely to help
Patients with cancers unrelated to ovarian or prostate cancer may not receive direct benefits from this research.
What this research studies
This research investigates the role of PD-L1, a protein found on the surface of cells, in regulating the stability of mRNA related to anti-apoptotic genes in ovarian and prostate cancer cells. The study aims to understand how PD-L1 influences the expression of these genes, which can help cancer cells evade death. By examining the mechanisms of PD-L1's action, including its ability to bind to gene promoters and mRNAs, the research seeks to uncover new insights into cancer cell survival and potential therapeutic targets. Patients may benefit from findings that could lead to improved cancer treatments through enhanced understanding of immune responses.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing cancer therapies by targeting PD-L1's role in mRNA regulation.
How similar studies have gone: Other research has shown promising results in targeting PD-L1 for cancer treatment, indicating that this approach may yield valuable insights.
Where this research is happening
-
St. John's University
Queens, United States Active
Researchers
- Principal investigator: Vancurova, Ivana — St. John's University
- Study coordinator: Vancurova, Ivana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.